Navigation Links
Iomai Stockholders Approve Merger With Intercell Subsidiary
Date:8/1/2008

GAITHERSBURG, Md., Aug. 1 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) announced today that its stockholders approved the merger of Iomai with a wholly-owned subsidiary of Intercell AG. Approximately 71.6 percent of Iomai's outstanding shares entitled to vote at the special meeting approved the merger, representing approximately 99.9 percent of the votes cast. The transaction remains subject to certain closing conditions. Assuming satisfaction of the remaining conditions, the transaction is anticipated to be completed on or about Aug. 5, 2008.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
2. Iomai Announces Year-End 2007 Financial Results and Business Progress
3. Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
4. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
5. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
6. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
7. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
8. Milestone Scientific to Host 2008 Annual Meeting of Stockholders on Thursday, June 5, 2008 in New York City
9. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
10. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
11. Edwards Lifesciences to Webcast Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to ... presented by The Conference Forum in Boston on April 3-4, 2017. The CTC conference ... clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also ...
(Date:3/27/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is now offering a 3 ... who want to have their DarioHealth products reimbursed by ... agreements with partners across the U.S. who will be ... will supply and bill the customer,s insurance for their ...
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):